This is a timely editorial comment. Malmstrom highlightswhat is perhaps the least investigated and therefore leastevidence-based aspect of the management of NMIBC -–theissue of follow-up cystoscopy surveillance schedules [1]. Hepoints out that whilst recurrence rates for NMIBC havefallen steadily, the schedules have remained unchangedmeaning that the number of negative cystoscopies hasdoubled. He asks whether low-risk Ta tumours need to befollowed up for more than 1 year if they have had a clearflexible cystoscopy at 3 and 12 months. I would agree withthese proposals for low-risk patients. This strategy hasbeen carried out by most departments in the UK followinga similar recommendation by NICE in 2015 [2]. The resultsof a National UK questionnaire survey was presented at the2018 EAU Annual Meeting and showed that 3 years afteradopting this strategy in the UK National Health Service,there were no reported adverse outcomes including pro-gression to MIBC [3]. Anecdotally, such a strategy is popu-larwithpatientsaslongastheyaretoldthisfromthebeginning. Indeed, many patients welcome being dis-charged as there are often benefits such as reduced premi-ums for travel and life insurance

Title

Hanood Abu Rass

Publisher

Scandinavian Journal of Urology

Publisher Country

United Kingdom

Publication Type

Prtinted only

Volume

54

Year

2020

Pages

2